



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Latanoprost 50micrograms/ml / Timolol 5mg/ml
(Fixapost®) preservative free eye drops, 0.2ml unit dose

Tier 2 – medium impact

Date of issue: 09/07/2026

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Latanoprost 50micrograms/ml / Timolol [0.5%] 5mg/ml (Fixapost®) preservative free eye drops, 0.2ml unit dose, are out of stock until January 2027.
- Latanoprost 50micrograms/ml / Timolol [0.5%] 5mg/ml (Vizilatan Duo®) preservative free eye drops remain available but cannot support increased demand.
- Latanoprost 50micrograms/ml / Timolol 5mg/ml eye drops (containing preservatives) remain available.
- Timolol (Eysano®) 5mg/ml [0.5%] preservative free eye drops remain available but cannot support increased demand.
- Timolol (Eysano®) 2.5mg/ml [0.25%] preservative free eye drops are out of stock until September 2026.
- **Latanoprost (Monopost®) 50micrograms/ml preservative free eye drops, 0.2ml unit dose, remain available and can support increased demand.**
- **Timolol (Tiopex®) 1mg/g [0.1%] preservative free eye gel, 0.4g unit dose, remains available and can support increased demand**

ACTIONS REQUIRED

Prescribers should not initiate new patients on Fixapost® preservative free eye drops until the supply issue has resolved.

Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should:

- establish reason for use of a preservative free product and consider if a preservative containing product equivalent to Fixapost® could be trialled in some patients (see supporting information);
- if a preservative free product is deemed necessary, consider appropriateness of prescribing latanoprost (Monopost®) preservative free eye drops with a lower strength (0.1%) preservative free timolol product (Tiopex® eye gel), ensuring that patients are counselled on how to administer Tiopex®, as well as on sequential administration of the components (see supporting information);
- take into account treatment history including hypersensitivity or adverse reactions to topical eye preparations; and

Information produced by DHSC and disseminated by HSCB Pharmacy and Medicines Management Team. For most up-to-date information, visit <http://www.hscbusiness.hscni.net/services/3065.htm>

- where patients are on extended follow-up, or are being seen through diagnostic pathways, notify the glaucoma centre responsible for the patient's care to ensure appropriate monitoring is in place and intraocular pressure control is maintained following the change in treatment.

Where the above action is not appropriate, seek specialist advice on treatment options.

Supporting information

Clinical Information

Fixapost® contains the prostaglandin analogue, latanoprost (50micrograms/ml) and beta blocker, timolol (5mg/ml [0.5%]). It is licensed for use in adults for the reduction of intraocular pressure in those with open angle glaucoma and ocular hypertension who are insufficiently responsive to either topical beta-blockers or prostaglandin analogues. It is presented as single dose containers and administered once daily, in the morning.

Of the components of Fixapost® available as preservative free products and able to support the gap in market, Monopost® provides the same strength of latanoprost (50micrograms/ml) but Tiopex® is a lower strength timolol product (0.1%), however, specialists consider that concentration can be changed during a shortage to ensure treatment is not omitted, and also ensuring least disruption to eye services.

After administering latanoprost, allow at least 15 minutes before administering Tiopex®. The eye gel should be the last medication instilled.

Preservative-free products may be recommended if a patient is using eye drops more than 6 times a day, wears soft or hybrid contact lenses, has a chronic eye disease, or is on multiple preserved topical medication, has a preservative allergy, has ocular surface disease or inflammation, or if there is evidence of toxicity

Links to further information:

- SmPC Fixapost® Preservative Free Eye Drops [Fixapost Preservative Free Eye Drops - Summary of Product Characteristics \(SmPC\) - \(emc\) | 9830](#)
- SmPC MONOPOST® (latanoprost) 50 mcg/ml eye drops, solution in single-dose container [MONOPOST latanoprost 50 mcg/ml eye drops, solution in single-dose container - Summary of Product Characteristics \(SmPC\) - \(emc\) | 2978](#)
- SmPC TIOPEX® (timolol) 1 mg/g, eye gel in single-dose container [TIOPEX timolol 1 mg/g, eye gel in single-dose container - Summary of Product Characteristics \(SmPC\) - \(emc\) | 4807](#)
- BNF Latanoprost with timolol [Latanoprost with timolol | Drugs | BNF | NICE](#)
- BNF Treatment summary - Glaucoma and ocular hypertension <https://bnf.nice.org.uk/treatment-summaries/glaucoma-and-ocular-hypertension/>
- CKS Glaucoma <https://cks.nice.org.uk/topics/glaucoma/>